Novartis to pay $245 mln to end antitrust cases over Exforge drug generics

Novartis AG (NOVN.S) said last week it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.